aTyr Pharma Inc. (NASDAQ:LIFE) went up by 3.85% from its latest closing price compared to the recent 1-year high of $8.33. The company’s stock price has collected -2.92% of loss in the last five trading sessions. Press Release reported 15 hours ago that aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor
Is It Worth Investing in aTyr Pharma Inc. (NASDAQ :LIFE) Right Now?
Plus, the 36-month beta value for LIFE is at 2.12. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for aTyr Pharma Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $15.67. LIFE currently public float of 13.32M and currently shorts hold a 2.53% ratio of that float. Today, the average trading volume of LIFE was 1.48M shares.
LIFE’s Market Performance
LIFE stocks went down by -2.92% for the week, with a monthly drop of -9.81% and a quarterly performance of 16.13%, while its annual performance rate touched 61.19%. The volatility ratio for the week stands at 6.89% while the volatility levels for the past 30 days are set at 11.73% for aTyr Pharma Inc.. The simple moving average for the period of the last 20 days is -10.61% for LIFE stocks with a simple moving average of 3.92% for the last 200 days.
Analysts’ Opinion of LIFE
Many brokerage firms have already submitted their reports for LIFE stocks, with H.C. Wainwright repeating the rating for LIFE by listing it as a “Buy.” The predicted price for LIFE in the upcoming period, according to H.C. Wainwright is $13 based on the research report published on August 17th of the previous year 2020.
ROTH Capital, on the other hand, stated in their research note that they expect to see LIFE reach a price target of $15. The rating they have provided for LIFE stocks is “Buy” according to the report published on March 04th, 2020.
Oppenheimer gave a rating of “Outperform” to LIFE, setting the target price at $8 in the report published on March 02nd of the previous year.
LIFE Trading at -11.77% from the 50-Day Moving Average
After a stumble in the market that brought LIFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.14% of loss for the given period.
Volatility was left at 11.73%, however, over the last 30 days, the volatility rate increased by 6.89%, as shares sank -0.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.64% upper at present.
During the last 5 trading sessions, LIFE fell by -2.92%, which changed the moving average for the period of 200-days by +4.85% in comparison to the 20-day moving average, which settled at $4.83. In addition, aTyr Pharma Inc. saw 11.34% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at LIFE starting from Broadfoot Jill Marie, who sale 390 shares at the price of $7.66 back on Feb 09. After this action, Broadfoot Jill Marie now owns 9,833 shares of aTyr Pharma Inc., valued at $2,987 using the latest closing price.
Shukla Sanjay, the President and CEO of aTyr Pharma Inc., sale 778 shares at $7.66 during a trade that took place back on Feb 09, which means that Shukla Sanjay is holding 8,298 shares at $5,959 based on the most recent closing price.
Stock Fundamentals for LIFE
Current profitability levels for the company are sitting at:
- -152.19 for the present operating margin
The net margin for aTyr Pharma Inc. stands at -155.18. The total capital return value is set at -47.87, while invested capital returns managed to touch -57.48. Equity return is now at value -45.70, with -35.60 for asset returns.
Based on aTyr Pharma Inc. (LIFE), the company’s capital structure generated 7.07 points at debt to equity in total, while total debt to capital is 6.61. Total debt to assets is 5.78, with long-term debt to equity ratio resting at 4.35. Finally, the long-term debt to capital ratio is 4.07.
When we switch over and look at the enterprise to sales, we see a ratio of 0.57, with the company’s debt to enterprise value settled at 0.38. The receivables turnover for the company is 10.26 and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.06.